Nanobiotix S.A. (NBTX)

Every figure this model derived for NBTX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 538,000 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-12-31
cash 52,750,000 CashAndCashEquivalents 2025-12-31
current assets 62,750,000 CurrentAssets 2025-12-31
current liabilities 57,507,000 CurrentLiabilities 2025-12-31
equity -84,483,000 Equity 2025-12-31
interest expense 15,233,000 FinanceCosts 2025-12-31
ocf -33,422,000 CashFlowsFromUsedInOperatingActivities 2025-12-31
revenue 29,643,000 RevenueFromContractsWithCustomers 2025-12-31
sbc 3,539,000 ExpenseFromSharebasedPaymentTransactionsWithEmployees 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up NBTX on one particular measure came for.

RatioValue
cash operating margin-19.51
current ratio1.09
current ratio reported1.09
dilution pct1.17
fcf margin-114.56
interest cover-0.71
operating margin-36.49
owner earnings margin-126.5
revenue growth-355.34
revenue growth per share-352.38
rule of 40-391.84
sbc pct revenue11.94

What to be careful about

What this model itself distrusts about NBTX's figures. Written by the derivation as it ran, not added afterwards.